Get the Stockscreener App
2.25
0.00%
0.00
Pre-market:
2.21
-0.04
-1.78%
Phio Pharmaceuticals Corp stock is traded at $2.25, with a volume of 170.94K.
It is up +0.00% in the last 24 hours and down -10.00% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$2.25
Open:
$2.24
24h Volume:
170.94K
Relative Volume:
0.13
Market Cap:
$10.80M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.2759
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
-3.43%
1M Performance:
-10.00%
6M Performance:
+19.05%
1Y Performance:
-14.45%
1-Day Range:
$2.20
$2.28
1-Week Range:
$2.19
$2.47
52-Week Range:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
2.25 | 11.18M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Best Value Stocks to Buy for May 28th - The Globe and Mail
Using Bollinger Bands to evaluate Phio Pharmaceuticals Corp.Buy and Exit Strategy Based on Momentum - Newser
Why Phio Pharmaceuticals Corp. stock attracts strong analyst attentionReal-Time AI Sentiment and Price Forecast - Newser
Combining machine learning predictions for Phio Pharmaceuticals Corp.Technical Analysis of Growth Stock Opportunities - Newser
Using Ichimoku Cloud for Phio Pharmaceuticals Corp. technicalsTechnical Entry Plan with Risk Minimization - Newser
Phio Pharmaceuticals Corp expected to post a loss of 36 cents a shareEarnings Preview - TradingView
When is the best time to exit Phio Pharmaceuticals Corp.Intraday Price Forecast Using Volume Models - Newser
Common Warts Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Pipeline Analysis | Verrica Pharmaceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Ph - Barchart.com
Is Phio Pharmaceuticals Corp. meeting your algorithmic filter criteriaFree Weekly Setup With 3x Return Potential - Newser
How strong is Phio Pharmaceuticals Corp. company’s balance sheetTriple returns potential - Jammu Links News
What are the latest earnings results for Phio Pharmaceuticals Corp.Unlock powerful stock screening techniques - Jammu Links News
Is Phio Pharmaceuticals Corp. stock overvalued or undervaluedAchieve breakthrough gains with smart trades - Jammu Links News
What analysts say about Phio Pharmaceuticals Corp. stockIdentify safe investments with exceptional yields - Jammu Links News
What are Phio Pharmaceuticals Corp. company’s key revenue driversBuild a winning investment portfolio - Jammu Links News
What makes Phio Pharmaceuticals Corp. stock price move sharplyStay ahead with daily expert stock picks - Jammu Links News
How volatile is Phio Pharmaceuticals Corp. stock compared to the marketFree Investment Community - Jammu Links News
How does Phio Pharmaceuticals Corp. generate profit in a changing economyFree Stock Selection - Jammu Links News
What catalysts could drive Phio Pharmaceuticals Corp. stock higher in 2025Achieve rapid growth with smart investments - jammulinksnews.com
How does Phio Pharmaceuticals Corp. compare to its industry peersFree Stock Market Knowledge Sharing - Jammu Links News
Should I hold or sell Phio Pharmaceuticals Corp. stock in 2025Triple-digit growth rates - Jammu Links News
What is the risk reward ratio of investing in Phio Pharmaceuticals Corp. stockPost Market Opportunities With High Returns - Jammu Links News
What analysts say about Phio Pharmaceuticals Corp. stock outlookEntry Level Investment Outlook Forecast - beatles.ru
Is it the right time to buy Phio Pharmaceuticals Corp. stockMarket Forecast Planner To Watch Now - Jammu Links News
Real time alert setup for Phio Pharmaceuticals Corp. performanceTrade Setups With Clear Risk Limits Highlighted - metal.it
Phio Pharmaceuticals Issues New Warrants for $2.5M - TipRanks
Trading Bots Trigger Alerts on Phio Pharmaceuticals Corp. ActivityTrend Analysis for Safer Trades Gains Popularity - metal.it
Phio Pharmaceuticals shares fall 6.93% intraday despite announcing a drug substance development services agreement. - AInvest
Evaluating Phio Pharmaceuticals Corp. with trendline analysisHigh Return Idea With Technical Filter - Newser
Is Phio Pharmaceuticals Corp. Stock a Smart Buy in 2025 Investment Analysis InsideFree Growth Investment Group - Newser
Does Phio Pharmaceuticals Corp. stock perform well during market downturnsBreakneck growth rates - Jammu Links News
What institutional investors are buying Phio Pharmaceuticals Corp. stockGet real-time alerts on top-performing stocks - Jammu Links News
Is Phio Pharmaceuticals Corp. Stock Overbought or Oversold RSI Indicator AnalysisShort Term High Return Strategy - Newser
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):